Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations
- PMID: 22842875
- DOI: 10.1007/s00401-012-1020-6
Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations
Abstract
Accumulation of the DNA/RNA binding protein fused in sarcoma (FUS) as inclusions in neurons and glia is the pathological hallmark of amyotrophic lateral sclerosis patients with mutations in FUS (ALS-FUS) as well as in several subtypes of frontotemporal lobar degeneration (FTLD-FUS), which are not associated with FUS mutations. Despite some overlap in the phenotype and neuropathology of FTLD-FUS and ALS-FUS, significant differences of potential pathomechanistic relevance were recently identified in the protein composition of inclusions in these conditions. While ALS-FUS showed only accumulation of FUS, inclusions in FTLD-FUS revealed co-accumulation of all members of the FET protein family, that include FUS, Ewing's sarcoma (EWS) and TATA-binding protein-associated factor 15 (TAF15) suggesting a more complex disturbance of transportin-mediated nuclear import of proteins in FTLD-FUS compared to ALS-FUS. To gain more insight into the mechanisms of inclusion body formation, we investigated the role of Transportin 1 (Trn1) as well as 13 additional cargo proteins of Transportin in the spectrum of FUS-opathies by immunohistochemistry and biochemically. FUS-positive inclusions in six ALS-FUS cases including four different mutations did not label for Trn1. In sharp contrast, the FET-positive pathology in all FTLD-FUS subtypes was also strongly labeled for Trn1 and often associated with a reduction in the normal nuclear staining of Trn1 in inclusion bearing cells, while no biochemical changes of Trn1 were detectable in FTLD-FUS. Notably, despite the dramatic changes in the subcellular distribution of Trn1 in FTLD-FUS, alterations of its cargo proteins were restricted to FET proteins and no changes in the normal physiological staining of 13 additional Trn1 targets, such as hnRNPA1, PAPBN1 and Sam68, were observed in FTLD-FUS. These data imply a specific dysfunction in the interaction between Trn1 and FET proteins in the inclusion body formation in FTLD-FUS. Moreover, the absence of Trn1 in ALS-FUS provides further evidence that ALS-FUS and FTLD-FUS have different underlying pathomechanisms.
Similar articles
-
FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.Brain. 2011 Sep;134(Pt 9):2595-609. doi: 10.1093/brain/awr201. Epub 2011 Aug 19. Brain. 2011. PMID: 21856723 Free PMC article.
-
Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.Neuropathol Appl Neurobiol. 2013 Feb;39(2):157-65. doi: 10.1111/j.1365-2990.2012.01274.x. Neuropathol Appl Neurobiol. 2013. PMID: 22497712 Free PMC article.
-
FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.J Neurosci. 2014 Jun 4;34(23):7802-13. doi: 10.1523/JNEUROSCI.0172-14.2014. J Neurosci. 2014. PMID: 24899704 Free PMC article.
-
FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis.Brain Res. 2012 Jun 26;1462:40-3. doi: 10.1016/j.brainres.2011.12.010. Epub 2011 Dec 13. Brain Res. 2012. PMID: 22261247 Review.
-
Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.Rev Neurol (Paris). 2013 Oct;169(10):793-8. doi: 10.1016/j.neurol.2013.07.019. Epub 2013 Sep 5. Rev Neurol (Paris). 2013. PMID: 24011641 Review.
Cited by
-
Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma.J Biol Chem. 2019 Jul 19;294(29):11286-11296. doi: 10.1074/jbc.RA119.009494. Epub 2019 Jun 5. J Biol Chem. 2019. PMID: 31171724 Free PMC article.
-
Traffic jam at the nuclear pore: All roads lead to nucleocytoplasmic transport defects in ALS/FTD.Neurobiol Dis. 2020 Jul;140:104835. doi: 10.1016/j.nbd.2020.104835. Epub 2020 Mar 14. Neurobiol Dis. 2020. PMID: 32179176 Free PMC article. Review.
-
Disrupted neuronal trafficking in amyotrophic lateral sclerosis.Acta Neuropathol. 2019 Jun;137(6):859-877. doi: 10.1007/s00401-019-01964-7. Epub 2019 Feb 5. Acta Neuropathol. 2019. PMID: 30721407 Free PMC article. Review.
-
Abl kinase-mediated FUS Tyr526 phosphorylation alters nucleocytoplasmic FUS localization in FTLD-FUS.Brain. 2023 Oct 3;146(10):4088-4104. doi: 10.1093/brain/awad130. Brain. 2023. PMID: 37071594 Free PMC article.
-
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD.Mol Neurodegener. 2024 Jan 22;19(1):8. doi: 10.1186/s13024-023-00698-1. Mol Neurodegener. 2024. PMID: 38254150 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous